Fresh from its clinical success with caplacizumab, Ablynx NV has priced its initial US public offering totaling $200m, propelling the company's market capitalization over the €1bn mark.
The Belgium-headquartered group has listed on the Nasdaq after selling 11.4 million American Depositary Shares (ADS) priced at $17.50 each....